Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Pour L, Szarejko M, Bila J, Schjesvold FH, Spicka I, Maisnar V, Jurczyszyn A, Grudeva-Popova Z, Hájek R, Usenko G, Thuresson M, Norin S, Jarefors S, Bakker NA, Richardson PG, Mateos MV. Pour L, et al. Among authors: thuresson m. Haematologica. 2024 Mar 1;109(3):895-905. doi: 10.3324/haematol.2023.283509. Haematologica. 2024. PMID: 37646660 Free PMC article. Clinical Trial.
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.
Sonneveld P, Richardson PG, Ludwig H, Dimopoulos MA, Schjesvold FH, Hájek R, Abdulhaq H, Thuresson M, Norin S, Bakker NA, Mateos MV. Sonneveld P, et al. Among authors: thuresson m. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):687-696. doi: 10.1016/j.clml.2023.05.004. Epub 2023 May 6. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37355418 Free article.
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Schjesvold FH, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, Pour L, Spicka I, Dimopoulos MA, Masszi T, Chernova NG, Sandberg A, Thuresson M, Norin S, Bakker NA, Mateos MV, Richardson PG, Sonneveld P. Schjesvold FH, et al. Among authors: thuresson m. Haematologica. 2024 Jul 1;109(7):2331-2336. doi: 10.3324/haematol.2023.284635. Haematologica. 2024. PMID: 38426292 Free PMC article. Clinical Trial. No abstract available.
PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma.
Pour L, Micheva I, Usenko G, Mikala G, Masszi T, Simeonova K, Thuresson M, Huledal G, Norin S, Bakker NA, Minarik J. Pour L, et al. Among authors: thuresson m. Clin Lymphoma Myeloma Leuk. 2024 Jun;24(6):e267-e275.e2. doi: 10.1016/j.clml.2024.02.012. Epub 2024 Feb 23. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38490927 Free article. Clinical Trial.
Clinical Characteristics of Necrotizing Enterocolitis Diagnosed by Independent Adjudication of Abdominal Radiographs, Laparotomy, or Autopsy in Preterm Infants in the "Connection Trial".
Neu J, Singh R, Demetrian M, Flores-Torres J, Hudak M, Zupancic JA, Kronström A, Rastad J, Strömberg S, Thuresson M; “Connection Study” Group. Neu J, et al. Among authors: thuresson m. Am J Perinatol. 2025 Jan;42(2):268-280. doi: 10.1055/s-0044-1788275. Epub 2024 Jul 10. Am J Perinatol. 2025. PMID: 38986486 Free PMC article. Clinical Trial.
104 results